lodibet 464

lodibet 464

live Updated 1m ago Longhorns-Aggies rivalry returns Texas and Texas A&M are facing off for the first time since 2011. And the winner will head to the SEC Championship Game. Kickoff: 7:30 p.m. Where to watch: ABC. Streaming: Try Fubo for free. Latest odds: Texas, -6 . Subscribe to The Athletic on an exclusive offer here . Watch today’s game on Fubo and find the best ticket deals on StubHub . Find some consistency Texas' defense has been strong all season. It's second nationally in total defense and third in scoring defense. That's not the problem. The offense, however, has been inconsistent and sloppy. It's time for that to stop. The Longhorns need to find their rhythm on offense at the most important time of the season, especially on the road against their biggest rivals. Advertisement Run the ball, A&M The Aggies have to be able to run the ball. In all three of their losses against Notre Dame, South Carolina and Auburn, the Aggies had less than 170 yards rushing, including 146 against the Irish and 144 against the Gamecocks. Establish the run, limit the turnovers and let the rest of the offense open up from there. Ticket prices are as high as the stakes COLLEGE STATION, Texas — In the third quarter of Texas A&M’s blowout win against New Mexico State on Nov. 16, senior mechanical engineering student Ronaldo Resendiz left Kyle Field. Resendiz, a San Antonio native who will graduate in December, has attended most A&M home games in his four years on campus. With the Aggies’ eighth win of the season well in hand, he and a few friends ventured out for a quick meal so they could get back to the stadium as soon as possible — not for the end of the game, but to camp out for tickets to the home finale against hated rival Texas. Continue reading here. GO FURTHER The Texas-Texas A&M football rivalry is back, and the ticket prices are as high as the stakes By the numbers Passing offense: Texas 279.7 yards per game (17th nationally), Texas A&M 208.7 (86) Rushing offense: Texas 169.6 (58), Texas A&M 208.4 (17) Total offense: Texas 449.4 (18), Texas A&M 417.1 (44) Passing defense: Texas 143.5 (2), Texas A&M 227.7 (81) Rushing defense: Texas 104.0 (13), Texas A&M 128.4 (41) Total defense: Texas 247.5 (2), Texas A&M 356.1 (56) Scoring offense: Texas 36.5 points per game (15), Texas A&M 32.5 (36) Scoring defense: Texas 12.09 (3), Texas A&M 21.55 (T38) The coaches Steve Sarkisian is 35-15 in his fourth season as Texas' coach. He's 81-50 overall as a coach with stops at Washington and USC. Mike Elko is 8-3 in his first season as Texas A&M's coach. He is 24-12 overall as a coach with a stop at Duke. The series Texas leads 76-37-5 First meeting: Texas won 38-0 in 1894. Last meeting: Texas won 27-25 in 2011. Of note: The two programs faced off every year from 1915 to 2011.Cerity Partners LLC Buys 27,891 Shares of Robert Half Inc. (NYSE:RHI)CAN a Common Utility Tunnel (CUT) system, similar to the one in Putrajaya, prevent incidents like the recent tragedy where an Indian national was swallowed by a sinkhole in Jalan Masjid India? Kuala Lumpur mayor Datuk Seri Maimunah Mohd Sharif believes such a system could improve underground utility maintenance and prevent similar accidents in the future, but its feasibility hinges on careful planning and cost considerations. “From an engineering standpoint, it’s possible, but the challenge lies in retrofitting such a system into a dense, built-up urban area,” she told StarMetro when asked about the feasibility of building an underground tunnel for utilities and cables beneath Kuala Lumpur. “The CUT system, like the one in Putrajaya, is feasible for improving underground utility maintenance. “I have seen this in Japan, where there are miles and miles of utility and fibre-optic cables running underneath cities like Tokyo, but these were constructed decades ago. “In Kuala Lumpur, this could be considered for newer developments where there is still space to plan something like it,” she said. Previously, Minister in the Prime Minister’s Department (Federal Territories) Dr Zaliha Mustafa had told Parliament that Kuala Lumpur City Hall (DBKL) was urged to consider building a common utility system similar to Putrajaya’s to improve efficiency of the city’s underground utility system. She added that the system could also be integrated with the city’s control centre using telemetry technology for safety and monitoring. Maimunah, a trained urban planner, said Putrajaya was a greenfield area, making it suitable for underground tunnelling projects, as it offered flexibility and reduced risk of disrupting existing infrastructure. Putrajaya’s Common Utility Trench houses a mass of TNB, multimedia, telecommunication and fibre-optic cables, as well as Air Selangor, Gas Malaysia and chilled water pipes. “But Kuala Lumpur, being predominantly a brownfield area, is less suitable, though not impossible from an engineering perspective,” she said. (Brownfield sites are typically located in urban areas because they have previously been built upon, while greenfield sites have never been built on and can be found in the countryside or rural areas.) Putrajaya’s underground utility system was constructed between 1999 and 2006 at a cost of RM250mil. Located 3m beneath the core island, it spans 10.8km across Precincts 2, 3 and 4 and serves as the nerve centre for utility companies and service providers, exclusively supporting ministries and government buildings. It comprises a network of Tenaga Nasional Bhd (TNB) cables, Air Selangor and Gas Malaysia pipes, and multimedia and telecommunication fibre-optic cables, all neatly arranged. On the status of the utility mapping task force study following the Jalan Masjid India incident, Maimunah said the report would be ready by the end of the year. “But if utility companies had been unwilling to share their data before, the Jalan Masjid India incident has opened everyone’s eyes, and now all parties are willing to help and share information. “We have RM10mil allocated under Budget 2025 to conduct the utility mapping study, which will cover the Jalan Masjid India area and the CBD (central business district),” she said. In the Aug 23 incident, an Indian tourist, Vijayalakshmi Gali, fell into a 8m sinkhole. Her body has not been recovered. — By BAVANI MClinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares Outstanding

Political tension escalate in Odisha as Cong, BJD, BJP trade barbs over Modi’s remarks